Immunology

The US FDA approved Leqvelsi for alopecia areata, making it the third drug in the class for the indication after Lilly’s Olumiant and Pfizer’s Litfulo.

Big biopharma is struggling to find the next generation of cancer immunotherapies, but the sector’s smallest companies might just have the platforms of the future.

Flush with cash, the controlling stakeholder of Novo Nordisk’s life sciences investment arm is increasing its financing of other biopharma innovators.

Artiva grossed $167m by selling more shares than previously planned, but at a significantly lower price per share than it proposed earlier in the week, to fund its NK cell therapy programs.

New modalities and potential best-in-class challengers have excited investors in 2024 to date, but companies whose drugs have underperformed on the market have been punished.

The Munich-based firm looks to pioneer the novel iRhom2 mechanism to dial down inflammation while maintaining immune homeostasis.

The French drugmaker can now boast seven approvals for its huge-earning IL-4/IL-13 inhibitor.

A Phase IIb trial testing Cartesian’s autologous mRNA-engineered CAR-T therapy for the treatment of generalized myasthenia gravis (MG) met the primary endpoint.

The drug maker is spending $250m to acquire privately held Celsius and its lead candidate, a monoclonal antibody targeting TREM1 in inflammatory bowel disease.

Ensho Therapeutics is raising series A cash to develop Phase II-ready NSHO-101 (EA1080), a third oral ɑ4β7 integrin inhibitor attempting to take on Takeda’s blockbuster injectable Entyvio.

VX-880 is the first iteration of a cell therapy strategy which Vertex believes can bring curative treatment for Type 1 diabetes, but competition in this field is building.

AbbVie's rival interleukin-23 drug Skyrizi is now approved in the US for both principal types of inflammatory bowel disease – ulcerative colitis and Crohn’s disease. Tremfya may not be too far behind.